Angiogenesis targeting in breast cancer;Le ciblage de l'angiogenèse dans les cancers du sein

Bulletin du Cancer

Volumn 94, Issue SUPPL. 7, 2007, Pages

  Fumoleau, Pierre ^a   Coudert, Bruno ^a   Mayer, Françoise ^a   Isambert, Nicolas ^a   Favier, Laure ^a   Ferrant, Emmanuelle ^a  

^a CENTRE GEORGES FRANÇOIS LECLERC   (France)

Author keywords

Bevacizumab; Breast cancer; VEGF; VEGF R

Indexed keywords

3 (4 BROMO 2,6 DIFLUOROBENZYLOXY) 5 [3 [4 (1 PYRROLIDINYL)BUTYL]UREIDO] 4 ISOTHIAZOLECARBOXAMIDE; 4 (4 FLUORO 2 METHYL 5 INDOLYLOXY) 6 METHOXY 7 [3 (1 PYRROLIDINYL)PROPOXY]QUINAZOLINE; 5,6,7,13 TETRAHYDRO 12 (3 HYDROXYPROPYL) 9 ISOPROPOXYMETHYLINDENO[2,1 A]PYRROLO[3,4 C]CARBAZOL 5(12H) ONE DIMETHYLGLYCINE ESTER; ABT 869; AEE 7888; AG 028262; AGO 13736; ANGIOGENESIS INHIBITOR; AXITINIB; BEVACIZUMAB; BIBF 1120; BMS 582664; CAPECITABINE; CHIR 258; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; E 7080; GW 86034; JNJ 26483327; KRN 951; LAPATINIB; METALLOPROTEINASE INHIBITOR; METHOTREXATE; N (3,3 DIMETHYL 6 INDOLINYL) 2 (4 PYRIDINYLMETHYLAMINO)NICOTINAMIDE; NAVELBINE; OSI 930; PACLITAXEL; PAZOPANIB; PROTEIN TYROSINE KINASE INHIBITOR; REGENERON; SORAFENIB; SU 14813; SUNITINIB; TAMOXIFEN; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VATALANIB; XL 7184; XL 820; XL 999;

ASTHENIA; BREAST CANCER; BREAST METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CANCER TISSUE; CARDIOMYOPATHY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIARRHEA; DRUG EFFICACY; DRUG RESPONSE; DRUG TARGETING; FATIGUE; HUMAN; MONOTHERAPY; NAUSEA; NEOVASCULARIZATION (PATHOLOGY); NEUROPATHY; NEUTROPENIA; PROTEINURIA; REVIEW; SAMPLING; THROMBOCYTOPENIA; THROMBOSIS; TUMOR VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; BREAST NEOPLASMS; DRUG THERAPY, COMBINATION; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 36249000034     PISSN: 00074551     EISSN: 17696917     Source Type: Journal    
DOI: 10.1684/bdc.2007.0433     Document Type: Review

References (59)

1. Folkman J. Tumor angiogenesis : therapeutic implications. N Engl J Med 1971 ; 285 : 1182-6.
2. Brem SS, Gullino PM, Medina D. Angiogenesis : A marker for neoplastic transformation of mammary papillary hyperplasia. Science 1977 ; 195 : 880-2.
3. Jensen HM, Chen I, DeVault MR, et al. Angiogenesis induced by «normal» human breast tissue : A probable marker for precancer. Science 1982 ; 218 : 293-5.
4. Miller K, Sledge GW. Dimming the blood tide : angiogenesis, antiangiogenic therapy and breast cancer. In : Nabholtz JM, ed. Breast cancer management application of clinical and translational evidence to patient care (2nd ed). Philadelphia, PA : Lippincott Williams & Wilkins, 2003.
5. Salceda S, Caro J. Hypoxia-inducible factor 1alpha (HIF-1 α) protein is rapidly degraded by the ubiquitin-proteasome system under notmoxic conditions. Its stabilization by hypoxia depends on redox-induced changes. J Biol Chem 1991 ; 272 : 22642-7.
6. 2 tension. Proc Natl Acad Sci USA 1995 ; 92 : 5510-4.
7. Bos R, Zhong H, Hanrahan CF, et al. Levels of hypoxia-inducible factor-1 alpha during breast carcinogenesis. J Natl Cancer Inst 2001 ; 93 : 309-14.
8. Tronick SR, Aaronson SA. Growth factor and signal transduction. Molecular basis of cancer. Mendelsohn. Howley, Israel : Liotta. Eds Saunders, 1995.
9. Chia SK, Wykoff CC, Watson PH, et al. Prognostic significance of a novel hypoxia-regulated marker, carbonic anhydrase IX, in invasive breast carcinoma. J Clin Oncol 2001 ; 19 : 3660-8.
10. Wykoff CC, Beasley NJ, Watson PH, et al. Hypoxia-inducible expression of tumor-associated carbonic anhydrases. Cancer Res 2000 ; 60 : 7075-83.
11. Guinebretiere JM, Le Monique G, Gavoille A, et al. Angiogenesis and risk of breast cancer in women with fibrocystic disease. J Natl Cancer Inst 1994 ; 86 : 635-6.
12. Guidi AJ, Fischer L, Harris JR, et al. Microvessel density and distribution in ductal carcinoma in situ of the breast. J Natl Cancer Inst 1994 ; 86 : 614-9.
13. Guidi AJ, Schnitt SJ, Fischer L, et al. Vascular permeability factor (vascular endothelial growth factor) expression and angiogenesis in patients with ductal carcinoma in situ of the breast. Cancer 1997 ; 80 : 1945-53.
14. Gasparini G, Toi M, Gion M, et al. Prognostic significance of vascular endothelial growth factor protein in node-negative breast carcinoma. J Natl Cancer Inst 1997 ; 89 : 139-47.
15. Linderholm B, Grankvist K, Wilking N, Johansson M, Tavelin B, Henriksson R. Correlation of vascular endothelial growth factor content with recurrences, survival, and first relapse site in primary node-positive breast carcinoma after adjuvant treatment. J Clin Oncol 2000 ; 18 : 1423-31.
16. Gasparini G, Toi M, Miceli R, et al. Clinical relevance of vascular endothelial growth factor and thymidine phosphorylase in patients with node-positive breast cancer treated with either adjuvant chemotherapy or hormone therapy. Cancer J Sci Am 1999 ; 5 : 101-11.
17. Foekens JA, Peters HA, Grebenchtchikov N, et al. High tumor levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast cancer. Cancer Res 2001 ; 61 : 5407-14.
18. Borgstrom P, Gold DP, Hillan KJ, Ferrara N. Importance of VEGF for breast cancer angiogenesis in vivo : implications from intravital microscopy of combination treatments with an anti-VEGF neutralizing monoclonal antibody and doxorubicin. Anticancer Res 1999 ; 19 : 4203-14.
19. Ragaz J, Miller K, Badve S, et al. Adverse association of expressed vascular endothelial growth factor, Her2, Cox2, uPA and EMSY with long-term outcome of stage I-III breast cancer. Results from the British Columbia Tissue Microarray Project. Proc Am Soc Clin Oncol 2004 ; 23 : 8 (abstr 524).
20. Cobleigh M, Langmuir V, Sledge G, et al. A phase I/II dose-escalation trial of Bevacizumab in previously treated metastatic breast cancer. Semin Oncol 2003 ; 30(5 suppl 16) : 117-24.
21. Miller K, Chap L, Homes F, et al. Trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 2005 ; 23 : 792-9.
22. Miller KD, et al. A randomized Phase III trial of paclitaxel versus paclitaxel plus bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer : a trial coordinated by the ECOG (E2100). Proc San Antonio Breast Cancer Symp 2005 (abstract 3).
23. Burnstein HJ, Parker LM, Savoir J, et al. Phase II trial of the anti-VEGF antibody bevacizumab in combination with vinorelbine for refractory advanced breast cancer. Proc San Antonio Breast Cancer Symp 2002 (abstract 446).
24. Ramaswamy B, Rhoades CA, Kendra K, et al. CTEP-sponsored phase II trial of bevacizumab in combination with docetaxel in metastatic breast cancer. Proc San Antonio Breast Cancer Symp 2003 (abstract 224).
25. Miller K, Gradishar W, Moisa C, Sledge G, et al. Capecitabine plus bevacizumab in first line metastatic breast cancer : an interim safety and efficacy report of the first phase of xeloda plus avastin 1st line metastatic breast cancer trial. Proc San Antonio Breast Cancer Symp 2006 (abstract 2068).
26. Perez EA, Hillman DW, Kugker JW, et al. North Central cancer treatment group (NCCTG) N0432 : phase II trial of docetaxel with capecitabine and bevacizumab as first line chemotherapy for patients with metastatic breast cancer. Proc San Antonio Breast Cancer Symp 2006 (abstract 2069).
27. Wedam SB, Low JA, Yang LS, et al. Antiangiogenic and antitumor effects of bevacizumab in inflammatory and locally advanced breast cancer patients. J Clin Oncol 2006 ; 24 : 5.
28. Overmoyer B, Silverman P, Leeming R, et al. Phase II trial of neoadjuvant Docetaxel with or without Bevacizumab in patients with locally advanced breast cancer. Proc San Antonio Breast Cancer Symp 2004 (Abstract 2088).
29. Abrams TJ, Murray LJ, Pesenti E, et al. Preclinical evaluation of the tyrosine kinase inhibitor SU11248 as a single agent and in combination with «standard of care» therapeutic agents for the treatment of breast cancer. Mol Cancer Ther 2003 ; 2 : 1011-21.
30. Miller KD, Burstein HJ, Elias AD, et al. Phase II study of SU11248, a multitargeted receptor tyrosine kinase inhibitor, in patients with previously treated metastatic breast cancer. J Clin Oncol 2005 ; 23 : 19s-563.
31. Deprimo SE, Friece C, Huang X, et al. Effect of treatment with sunitinib malate, a multitargeted tyrosine kinase inhibitor, on circulating plasma levels of VEGF, soluble VEGF receptors 2 and 3, and soluble KIT in patients with metastatic breast cancer. J Clin Oncol 2006 ; 24 : 22s (abstract 578).
32. NIH. Information on Clinical Trials and Human Research. US National Institutes of Health. http://www.clinicaltrials.gov (http://www.clinical trials.gov/ct/search?term & sunitinib & submit & search).
33. NCI/CTEP. US National Institutes of Health. NCI Clinical Trials Information Site. www.cancer.gov. Pfizer Oncology. Clinical trials : Sunitinib. www.pfizeroncology.com/ClinicalTrialPO.aspx.
34. Polverino A, Coxon A, Starnes C, et al. AMG706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts. Cancer Res 2006 ; 66 : 8715-21.
35. Laughner E, Taghavi P, Chiles K, et al. HER2 signaling increases the rate of hypoxia-inducible factor 1alpha synthesis : novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Mol Cell Biol 2001 ; 21 : 3995-4004.
36. Epstein M, Ayala R, Tchekmedyian N, et al. HER2-overexpressing human breast cancer xenografts exhibit increased angiogenic potential mediated by vascular endothelial growth factor. Breast Cancer Res Treat 2002 ; 76 : S143 (abstract 570).
37. Pegram M, Yeon C, Ku N, et al. Phase I combined biological therapy of breast cancer using two humanized monoclonal antibodies directed against HER2 proto-oncogene and vascular endothelial growth factor. Breast Cancer Res Treat 2004 ; 88 : S124 (abstract 3039).
38. Konecny GE, Meng YG, Untch M, et al. Association between HER-2/neu and vascular endothelial growth factor expression predicts clinical outcome in primary breast cancer patients. Clin Cancer Res 2004 ; 10 : 1706-16.
39. Pegram M, Chang D, Dichmann RA, et al. Phase II combined biological therapy targeting the HER2 proto-oncogene and the vascular endothelial growth factor using trastuzumab and bevacizumab as first line treatment of HER2-amplified breast cancer. Proc San Antonio Breast Cancer Symp 2006 (Abstract 301).
40. Maity A, Pore N, Lee J, et al. Epidermal growth factor receptor transcriptionally up-regulates vascular endothelial growth factor expression in human glioblastoma cells via a pathway involving phosphatidylinositol 3′-kinase and distinct from that induced by hypoxia. Cancer Res 2000 ; 60 : 5879-86.
41. Clarke K, Smith K, Gullick WJ, et al. Mutant epidermal growth factor receptor enhances induction of vascular endothelial growth factor by hypoxia and insulin-like growth factor-1 via a PI3 kinase dependent pathway. Br J Cancer 2001 ; 84 : 1322-9.
42. Bruns CJ, Solorzano CC, Harbison MT, et al. Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma. Cancer Res 2000 ; 60 : 2926-35.
43. Petit AM, Rak J, Hung MC, et al. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo : Angiogenic implications for signal transduction therapy of solid tumors. Am J Pathol 1997 ; 151 : 1523-30.
44. Viloria-Petit A, Crombet T, Jothy S, et al. Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo : A role for altered tumor angiogenesis. Cancer Res 2001 ; 61 : 5090-101.
45. Rugo H, Dickler M, Scott J, et al. Circulating endothelial cell and tumor cell analysis in patients receiving bevacizumab and erlotinib for metastatic breast cancer. Breast Cancer Res Treat 2004 ; 88 : S142 (abstract 3088).
46. Miller KD, Sweeney CJ, Sledge GW. Redefining the target : Chemotherapeutics as antiangiogenics. J Clin Oncol 2001 ; 19 : 1195-206.
47. Gagliardi A, Collins DC. Inhibition of angiogenesis by antiestrogens. Cancer Res 1993 ; 53 : 533-5.
48. Gagliardi AR, Hennig B, Collins DC. Antiestrogens inhibit endothelial cell growth stimulated by angiogenic growth factors. Anticancer Res 1996 ; 16 : 1101-6.
49. Haran EF, Maretzek AF, Goldberg I, et al. Tamoxifen enhances cell death in implanted MCF7 breast cancer by inhibiting endothelium growth. Cancer Res 1996 ; 54 : 5511-4.
50. Sweeney C, Sledge G. Chemotherapy agents as antiangiogenic therapy. Cancer Conference Highlights 1999 ; 3 : 2-4.
51. Browder T, Butterfield CE, Kraling BM, et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 2000 ; 60 : 1878-86.
52. Klement G, Baruchel S, Rak J, et al. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest 2000 ; 105 : R15-R24.
53. Wild R, Dings R, Subramanian I, et al. Carboplatin selectively induces the VEGF stress response in endothelial cells : Potentiation of antitumor activity by combination treatment with antibody to VEGF. Int J Cancer 2004 ; 110 : 343-51.
54. Colleoni M, Rocca A, Sandri MT, et al. Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer : Antitumor activity and correlation with vascular endothelial growth factor levels. Ann Oncol 2002 ; 13 : 73-80.
55. Burnstein HJ, et al. Proc San Antonio Breast Cancer Symp 2005 (abstract 4).
56. Hortobagyi G, Weng D, Elias A, et al. Angiozyme treatment of stage IV metastatic breast cancer patients : Assessment of serum markets of angiogenesis. Breast Cancer Res Treat 2002 ; 76 : S97 (abstract 362).
57. Sparano JA, Bernardo P, Stephenson P, et al. Randomized phase III trial of marimastat versus placebo in patients with metastatic breast cancer who have responding or stable disease after first-line chemotherapy : Eastern Cooperative Oncology Group trial E2196. J Clin Oncol 2004 ; 22 : 4631-8.
58. Sledge G, Miller K, Haney L, et al. A phase I study of 2-methoxyestradiol in patients with refractory metastatic breast cancer. Proc Am Soc Clin Oncol 2002 ; 21 : 111a (abstract 441).
59. Miller K, Murry D, Curry E, et al. A phase I study of 2-methoxyestradiol plus docetaxel in patients with metastatic breast cancer. Proc Am Soc Clin Oncol 2002 ; 21 : 111a (abstract 442).